Answers are grounded in this paper and cite their sources.
We have developed a third-generation lentiviral vector pseudotyped with Sendai virus F and HN envelope proteins (rSIV.F/HN) expressing functional cystic fibrosis transmembrane conductance regulator (CFTR) as a gene therapy for cystic fibrosis (BI 3720931). Here, we assessed transduction efficiency and acute toxicology of the rSIV.F/HN vector expressing an enhanced green fluorescent protein (EGFP) reporter gene in non-human primates (NHPs). Intubated male cynomolgus monkeys received one aerosolized dose of vector ( n = 3) or placebo ( n = 3). Toxicology was assessed by histopathology, clinical pathology, cytokine levels, and changes in body and organ weight. Transduction efficiency was quantified by EGFP immunohistochemistry in airway epithelial cells and vector-specific mRNA and DNA in the lung 7 days post-dosing. There were no vector-related clinical observations, mortalities, or changes in body or organ weight. Clinical pathology and cytokine analyses were unremarkable. Minimal mixed-cell centriacinar inflammation was observed in 1/3 vector-treated animals. Airway epithelial cell transduction efficiency was 9%–12%. Genomic DNA vector integration was detected in 6.7% of lung epithelial cells. Vector-specific mRNA levels were ∼45× endogenous CFTR mRNA levels in lung epithelium and ∼16× in bronchial brushings. This study extends earlier findings of rSIV.F/HN-based in vivo gene transfer in mice to NHPs, demonstrating transduction efficiency without relevant toxicity.
No takes yet. Share an insight, caveat, or question.
Griesenbach et al. (2025) studied this question.